Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
Phase 3
Completed
- Conditions
- In-Stent Restenosis
- Interventions
- Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable StentProcedure: Brachytherapy
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 384
- Registration Number
- NCT00231257
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
Phase 3
Completed
- Conditions
- Carotid Artery Disease
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-07-20
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 1500
- Registration Number
- NCT00231231
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)
Phase 3
Completed
- Conditions
- Carotid Artery Disease
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 1300
- Registration Number
- NCT00231270
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
Phase 3
Completed
- Conditions
- Coronary Disease
- Interventions
- Device: CoStar Paclitaxel Drug Eluting Coronary Stent SystemDevice: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 1701
- Registration Number
- NCT00165035
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Christ Linder, Cincinatti, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath